

HERPES VACCINE DEVELOPMENT

JN-INTERNATIONAL MEDICAL CORPORATION

Prophylactic and Therapeutic Herpes Simplex Virus Vaccines


HSV-1 and HSV-2 are known to cause genital herpes, oral-facial infections (gingivostomatitis, labialis, pharyngitis) cutaneous infections (whitlow, herpes gladiatorum) ocular infections, neonatal herpes, herpes encephalitis, disseminated infection and erythema multiform.



Prophylactic and Therapeutic Herpes Simplex Virus Vaccines

Genital Herpes Vaccine

At our laboratories, we have generated and rationalized Herpes simplex virus type 1 subunit vaccines with adjuvant help are a suitable target for a vaccine, despite available HSV antiviral therapies, because the virus causes lifelong infection and significant medical and psychosocial morbidity. The vaccine may reduce HSV acquisition and disease severity. The HSV-epitope based HSV-2 vaccine may give broad and durable immunity across all mucosal surfaces to be effective and possible that the vaccine could reduce symptomatic disease and may eliminate asymptomatic shedding, which could inadvertently increase transmission from individuals who believe they are not infectious.



Jn-International's

Genital Herpes Vaccine

Discovery Research



45 million Americans with known genital herpes, and millions of others with various other forms of herpes virus infections, share the problem demonstrates that no herpes sufferer is alone.